
Walmart is expected to report a strong Q1 performance with US comparable sales rising about 4.5%, driven by over 25% growth in e-commerce, offsetting weaker physical store sales. Challenges include softer health and wellness trends and pharmacy pressures due to pricing laws and slower adoption of certain therapies. UBS expects operating income growth near the high end of Walmart's 6-8% target, with international business also performing well. Investors await Walmart's May 21 earnings report to see if potential EPS upside is reflected in updated guidance amid macroeconomic uncertainties.